UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status
Unique ID issued by UMIN C000000305
Receipt No. R000000386
Scientific Title Efficacy of PEG-IFN alpha-2b and Ribavirin after curative treatment of hepatitis C virus related hepatocellular carcinoma
Date of disclosure of the study information 2006/01/16
Last modified on 2006/01/15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Efficacy of PEG-IFN alpha-2b and Ribavirin after curative treatment of hepatitis C virus related hepatocellular carcinoma
Acronym PEG-IFN alpha-2b and Ribavirin Therapy
Scientific Title Efficacy of PEG-IFN alpha-2b and Ribavirin after curative treatment of hepatitis C virus related hepatocellular carcinoma
Scientific Title:Acronym PEG-IFN alpha-2b and Ribavirin Therapy
Region
Japan

Condition
Condition Hepatitis C virus related chronic liver disease
Classification by specialty
Hepato-biliary-pancreatic medicine Hepato-biliary-pancreatic surgery
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Investigate the effect of PEG-IFN alpha-2b and Ribavirin for the recurrence of hepatocellular carcinoma, survival, and safety in patients with chronic liver disease after curative treatment of hepatitis C virus related hepatocellular carcinoma by surgical resection or radiofrequency ablation
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Explanatory
Developmental phase Not applicable

Assessment
Primary outcomes Disease free survival
Key secondary outcomes 1) Survival
2) Sustained viral response
3) Sustained biochemical response
4) Safety

Base
Study type Interventional

Study design
Basic design Factorial
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 PEG-IFN alpha-2b 1.0microgram/kg/w+ Ribavirin 400-600mg/day for 48 weeks(Patients with age: under 65 years old, hemoglobin concentration: equal or over 10g/dl, white blood cell count: equal or over 1,500/mm3, blood neutrophil count: equal or over 750/mm3, and platelet count: equal or over 80,000/mm3)
Interventions/Control_2 PEG-IFN alpha-2b 0.5microgram/kg/w+ Ribavirin 200mg/day for 48 weeks (Patients other than age: under 65 years old, hemoglobin concentration: equal or over 10g/dl, white blood cell count: equal or over 1,500/mm3, blood neutrophil count: equal or over 750/mm3, and platelet count: equal or over 80,000/mm3)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Criteria before treatment of hepatocellular carcinoma
1) Patients with first occurrence or first recurrence (after more than 1 year from treatment of hepatocellular carcinoma) of hepatocellular carcinoma
2) Patients without portal venous invasion
Criteria after treatment of hepatocellular carcinoma
1) Patients with curative treatment of hepatocellular carcinoma by surgical resection or radiofrequency ablation
2) Patients passed 8 to 12 weeks after treatment of hepatocellular carcinoma and observed no recurrence by imaging test
3) Patients who can treat within 8 weeks after confirming no recurrence by imaging test
4) Hepatitis C virus related chronic liver disease patients with detectable serum HCV RNA
Key exclusion criteria 1) Patients with concomitant carcinoma except for hepatocelular carcinoma
2) Patients with experience of systemic anti-cancer drug treatment for hepatocellular carcinoma
3) Pregnant or lactating women and women who may be pregnant
4) Female patients or male patients with partners who may become pregnant who cannot practice contraception during treatment and 6 months after end of treatment
5) Male patients with pregnant partners who cannot comply with condom use during treatment and 6 months after end of treatment
6) History of hypersensitivity to ribavirin or other nucleoside analogues (acyclovir, ganciclovir, vidarabine etc.)
7) Inadequately controlled cardiac disease (myocardial infarction, cardiac failure, arrhythmia etc.)
8) Hemoglobinopathy (thalassemia, drepanocytic anemia etc.)
9) Chronic renal failure or renal function disorder with creatinine clearance of 50 mL/min or less
10) With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc.
11) Serious hepatic function disorder
12) Autoimmune hepatitis
13) History of hypersensitivity to PEG-IFN alpha-2b or other interferons
14) History of hypersensitivity to biological products such as vaccine
15) Patients receiving shosaiko-to
16) Judged by investigator to be not appropriate for inclusion in this study
Target sample size 40

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yukio Osaki
Organization Osaka Red Cross Hospital
Division name Department of Gastroenterology and Hepatology
Zip code
Address Fudegasaki-cho 5-30, Tennoji-ku, Osaka, Japan
TEL 06-6774-5111
Email

Public contact
Name of contact person
1st name
Middle name
Last name Toru Kimura
Organization Osaka Red Cross Hospital
Division name Department of Gastroenterology and Hepatology
Zip code
Address Fudegasaki-cho 5-30, Tennoji-ku, Osaka, Japan
TEL 06-6774-5111
Homepage URL
Email tookimura-gi@umin.ac.jp

Sponsor
Institute Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2006 Year 01 Month 16 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status
Date of protocol fixation
2005 Year 12 Month 20 Day
Date of IRB
Anticipated trial start date
2006 Year 01 Month 01 Day
Last follow-up date
2010 Year 12 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2006 Year 01 Month 14 Day
Last modified on
2006 Year 01 Month 15 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000386

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.